Pfizer Inc. $PFE Stake Reduced by Hourglass Capital LLC

Hourglass Capital LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.9% during the fourth quarter, HoldingsChannel reports. The firm owned 438,148 shares of the biopharmaceutical company’s stock after selling 32,390 shares during the period. Pfizer accounts for 2.4% of Hourglass Capital LLC’s portfolio, making the stock its 8th largest position. Hourglass Capital LLC’s holdings in Pfizer were worth $10,910,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Horizon Financial Services LLC raised its holdings in shares of Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the period. Grey Fox Wealth Advisors LLC purchased a new position in Pfizer in the 3rd quarter worth approximately $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer in the second quarter valued at approximately $30,000. Darwin Wealth Management LLC acquired a new stake in Pfizer in the second quarter valued at approximately $32,000. Finally, True Wealth Design LLC raised its stake in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $27.03 on Friday. The stock has a market capitalization of $153.70 billion, a PE ratio of 19.88 and a beta of 0.47. The business’s fifty day moving average price is $26.84 and its 200 day moving average price is $25.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.94.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.63 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage clinical wins broaden Pfizer’s pipeline beyond COVID — a partnered 6‑valent Lyme vaccine showed ~75% Phase 3 efficacy and several oncology/immunology programs met key endpoints, supporting a re‑rating of growth prospects. Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
• Positive Sentiment: Guggenheim raised its price target and reiterated a Buy, citing favorable risk/reward ahead of Phase 3 MEVPRO‑1 data — that analyst support can underpin short‑term investor interest. Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
• Positive Sentiment: Multiple bullish notes and “strong buy” theses are circulating after recent trial/portfolio progress, which can attract income and value investors looking for upside plus yield. Why Pfizer Remains A Strong Buy In 2026
• Neutral Sentiment: Jim Cramer mentioned PFE but said he needs more clarity on product flow — a reminder that mainstream TV coverage can move short‑term flows but hasn’t changed fundamentals. Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better”
• Neutral Sentiment: Citi and other outlets continue to rate PFE around Hold/Neutral — signaling mixed analyst conviction despite select upgrades. Citi Remains a Hold on Pfizer (PFE)
• Negative Sentiment: A bearish view argues Wall Street overestimates PFE’s target price, pointing to political threats (e.g., “TrumpRx”, most‑favored‑nation pricing) that could compress margins and support a multi‑year earnings downside. That policy risk is pressuring valuation. Pfizer: Why Wall Street Habitually Overestimates Target Price
• Negative Sentiment: Income‑focused coverage flags payout safety concerns: Pfizer’s high yield draws attention but raises questions about sustainability if earnings weaken, which can amplify downside for dividend investors. Income Investors Face a Hard Truth About Pfizer’s Payout Safety

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PFE. BMO Capital Markets restated an “outperform” rating and issued a $30.00 target price on shares of Pfizer in a research note on Monday, March 9th. UBS Group started coverage on shares of Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target on the stock. HSBC boosted their price objective on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Monday, March 2nd. Finally, Bank of America lowered their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.19.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.